Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in Japan: A Retrospective Database Study in Clinical Practice from 2012 to 2015

Akiko Matsui1 · Michihiro Morimoto1 · Hiroshi Suzuki1 · Thomas Laurent2 · Yoko Fujimoto1 · Yoshimi Inagaki3

Published online: 18 June 2018 © The Author(s) 2018

Abstract

Objectives To investigate changes in sedation practice during 2012–2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015.

Methods Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine.

Results DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures.

Conclusion The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change.

Key Points

After the approval of dexmedetomidine for procedural sedation in 2013, utilization of dexmedetomidine increased, widening the gap from the second most used sedative, propofol for catheter ablation; benzodiazepines predominated the sedative utilization for endoscopic examination and surgery without change in the order of utilization proportion.

Sedation practice has changed for catheter ablation after 2013, but not for gastrointestinal endoscopic examination or surgery.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40801-018-0136-y) contains supplementary material, which is available to authorized users.

Akiko Matsui
akiko.matsui@pfizer.com

1 Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan
2 Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003, Japan
3 Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503, Japan
1 Introduction

Sedation is a necessary component of invasive catheter ablation (CA) and gastrointestinal endoscopy performed under local anesthesia. Flunitrazepam (FZP) had been the only agent approved for procedural sedation under local anesthesia in Japan until 2013. Although efficacy and safety profiles vary according to the sedative, most of the available agents entail a risk of respiratory depression [1–4], possibly resulting in fatality [1, 3, 4]. Such a risk could be further exacerbated by co-administration with analgesics during CA and endoscopy.

In 2013, dexmedetomidine (DEX) was approved for an additional indication—i.e., procedural sedation under local anesthesia. DEX, a highly selective α2-adrenergic agonist, produces sedation while maintaining the patient’s ability to communicate [5, 6] and analgesic and anxiolytic effects [7, 8], with a minimal risk for respiratory depression [9–13]. Simultaneously, however, DEX inhibits sympathetic nervous activities, to cause hypotension and bradycardia; and stimulates α2B-adrenergic receptors in the vascular smooth muscle at high plasma concentrations (e.g., at the initial loading dose) to cause transient hypertension [11, 14, 15].

In Japan, prior to the additional indication for DEX, midazolam (MDZ) and diazepam (DZP) followed by propofol (PF) had been most frequently used for gastrointestinal endoscopy [16] and PF for CA [17]. During 2003–2007, sedative-related events were the most commonly reported complications, with high frequencies of respiratory depression, hypoxia, and apnea [18]. However, updated and comprehensive data covering all the diverse sedatives including the newly added DEX, which would be expected to alter the sedation trend, is still lacking.

Therefore, using a large “real-world” database, this study aimed to investigate changes in sedation practice for CA, gastrointestinal endoscopic examination (EE), and endoscopic surgery (ES) following the approval of an added indication (procedural sedation) for DEX in 2013. We assessed the following trends from 2012 to 2015: (1) sedative utilization; (2) sedative-analgesic combinations; and additionally, (3) incidence of complications.

2 Materials and Methods

This retrospective study used a pre-existing de-identified claims database. The Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects do not apply to a study exclusively using the de-identified data. Therefore, this study was not obligated to apply for ethical approval by an institutional review board and informed consent. This article adheres to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) consensus [19].

2.1 Data Source

This study used the health claims database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan). The database collects data from 247 acute-care hospitals distributed across Japan, covering more than 14 million patients as of the end of July 2016. The recorded information includes patient demographic data, diagnosis, prescription of drugs, treatment, and surgery. The database avoids personally identifiable information by de-identifying the data prior to incorporating them in the database.

2.2 Study Sample

We analyzed the data collected from April 2012 to March 2015. We included hospitals whose data were updated monthly for 2 years from April 2012 (92 hospitals). We first identified the procedures conducted with procedural sedation under local anesthesia according to the following criteria: records of (1) local anesthesia (Supplementary Table 1 in the electronic supplementary material (ESM)), and (2) prescription of DEX, PF, or MDZ, but (3) without a record of general anesthesia (Supplementary Table 2 in the ESM) on the same day as local anesthesia. The criteria yielded 1498 codes, 60 of which were identified to be related to CA, EE, or ES (Supplementary Table 3 in the ESM).

Thus, we included patients meeting the following criteria: (1) age ≥ 18 years; (2) recorded height and body weight; (3) use of local anesthesia; (4) having undergone CA, EE, and/OR ES (identified with the 60 codes); but (5) no record of general anesthesia on the same day as local anesthesia.

2.3 Definitions

Based on an expert review, we defined the sedatives, analgesics, and complications. The sedatives were DEX, PF, benzodiazepines (MDZ, DZP, FZP), barbiturates (thiamylal (TIA), thiopental (TIO)), and ketamine. Analgesics included fentanyl, remifentanil, pethidine (PET), morphine, flurbiprofen, buprenorphine, and pentazocine (PTZ). The sedatives and analgesics were identified using prescription records.

Symptoms that are commonly reported during procedural sedation under local anesthesia and that were evaluated as complications in this study were respiratory depression, hypertension, hypotension, tachycardia, bradycardia, and nausea and vomiting. Hypertension and hypotension were excluded from the analysis of CA because prophylactic medications are usually administered for blood pressure fluctuation during the procedure. We operationally defined the
complications using records of drug prescription, medical procedures, and medical devices (e.g., oxygen mask) that are commonly used to counteract the corresponding symptoms (Supplementary Table 4 in the ESM). We counted only the complications that occurred on the same date as CA, EE, or ES, but not those that occurred on the day before. Respiratory depression during EE and ES, however, was counted regardless of its occurrence on the day before the procedure.

2.4 Statistical Analysis

Data were summarized descriptively. Demographic data on the date of the first CA, EE, or ES procedure were summarized as the patient’s characteristics.

To evaluate a time trend of sedative utilization, we calculated the proportion of each sedative prescription and each sedative-analgesic combination (including a sedative alone), by procedure (CA, EE, ES), for each fiscal year (i.e., from 1 April to 31 March of the following year), using as the denominator the sum of the procedures, and the prescriptions of all the combinations (including a sedative alone), respectively.

To further understand the sedation trend during 2012–2015, we explored for the proportion of sedative use for each procedure—CA or endoscopy (EE + ES) by sedative. The proportions were calculated by dividing the number of CA or endoscopic procedures by the sum of the prescriptions for each sedative. Because the duration and level of invasiveness may decide the sedatives used for endoscopy, we also calculated the proportion of procedures by site (upper and lower bowel for EE and ES) for each sedative by dividing the number of procedures (i.e., upper- or lower-bowel EE, or upper- or lower-bowel ES) by the total sedative prescriptions for endoscopy.

For analyzing complications, we calculated the annual occurrence of each complication by procedure (CA, EE, ES). In addition, we calculated the occurrence of each complication by the sedative-analgesic combination.

All analyses were conducted using SAS release 9.4 software (SAS Institute Inc., Cary, NC, USA).

3 Results

3.1 Demographic Characteristics

Of the 129,439 patients included in this study, 3483, 99,917, and 26,039 patients underwent CA, EE, and ES, respectively (Table 1). The mean (SD) ages of patients were higher for endoscopy than for CA [CA: 63.31 (13.01) vs. EE: 67.69 (14.38) vs. ES: 69.71 (13.47)]. The proportion of men was slightly greater than that of women for all the procedures.

3.2 Time Trend of Sedative Utilization by Procedure

From 2012 to 2015, DEX was most commonly used for CA, followed by PF (Fig. 1a). Although the order of DEX and PF did not change, the proportion of DEX increased from 30 to 36% and that of PF slightly decreased from 29 to 27% to gradually widen the gap between DEX and PF, which had been almost equally used in 2012. The third most commonly used sedative prior to 2014 (TIA) was replaced by TIO in 2015. The other sedatives were rarely or never used (MDZ and DZP < 5%, FZP and ketamine 0%).

The order of utilization proportions did not largely change for EE (Fig. 1b). Benzodiazepines dominated the top three places, accounting for > 90% of the sedative utilization each year. MDZ was used most often throughout the study period (> 50%). The other sedatives, including DEX, were rarely or never used (PF ≤ 1%, others 0%).

The order of utilization proportions did not largely change for ES (Fig. 1c). Benzodiazepines dominated the top three places, accounting for > 90% of the sedative use each year. MDZ was used most often throughout the study period (> 50%). The other sedatives, including DEX, were rarely or never used for EE, whereas use of PF increased (from 3 to 4% from 2012 to 2015). After 2013, the proportions of DEX and PF slightly increased (DEX from 0 to 2% and PF from 3 to 4% from 2013 to 2015).

3.3 Usage of Each Sedative

Figure 2 indicates the proportion of procedures performed under sedation. DEX was used more often for CA (68.5%) than for endoscopy (31.5%) (Fig. 2a). Of the endoscopic procedures, the proportions of utilization for EE and ES were 17.1 and 82.9%, respectively. Regarding the procedural endoscopic sites, DEX was used the most for ES of the upper bowel (68.5%) (Fig. 2b).

TIA and TIO were also mostly used for CA (CA vs. endoscopy: TIA 99.2 vs. 0.8% and TIO 99.6 vs. 0.4%, respectively) (Fig. 2a).

PF was used more for endoscopy (65.6%) than for CA (34.4%) (Fig. 2a). Of the endoscopic procedures, the proportions of utilization for EE and ES were 45.0 and 55.0%, respectively. Regarding the procedure sites, PF was used the most for ES of the upper bowel (47.3%) (Fig. 2b).

The trend of usage was similar among benzodiazepines (MDZ, DZP, FZP), which were mostly used for endoscopy (CA vs. endoscopy: MDZ 0.1 vs. 99.9%, DZP 0.6 vs. 99.4%, FZP 0 vs. 100%) (Fig. 2a). Of the endoscopic procedures, benzodiazepines were used most often for EE of the upper bowel (MDZ 66.7%, DZP 70.3%, FZP 65.6%) (Fig. 2b).

Endoscopy accounted for most of the procedures without sedation (CA 0.5% and endoscopy 99.5%) (Fig. 2a). Of the
Table 1  Patient demographic characteristics

|        | All | DEX | PF  | MDZ | DZP | FZP | TIA | TIO | Ketamine | No sedative |
|--------|-----|-----|-----|-----|-----|-----|-----|-----|----------|-------------|
| **CA** |     |     |     |     |     |     |     |     |          |             |
| N      | 3483| 1675| 1310| 101 | 150 | 1   | 732 | 835 | 0        | 996         |
| Age, years | 63.31 ± 13.01 | 64.94 ± 11.13 | 64.12 ± 11.41 | 63.52 ± 11.28 | 65.10 ± 13.79 | 69  | 64.04 ± 11.18 | 64.60 ± 11.18 | – | 60.90 ± 15.59 |
| < 65 years | 1577 (45.28) | 678 (40.48) | 557 (42.52) | 52 (51.49) | 60 (40.00) | 0 (0) | 309 (42.21) | 349 (41.80) | – | 522 (52.41) |
| ≥ 65 years | 1906 (54.72) | 997 (59.52) | 753 (57.48) | 49 (48.51) | 90 (60.00) | 1 (100) | 423 (57.79) | 486 (58.20) | – | 474 (47.59) |
| Sex    |     |     |     |     |     |     |     |     |          |             |
| Male   | 2261 (64.92) | 1138 (67.94) | 904 (69.01) | 71 (70.3) | 103 (68.67) | 1 (100) | 309 (42.21) | 349 (41.80) | – | 553 (55.52) |
| Female | 1222 (35.08) | 537 (32.06) | 406 (30.99) | 30 (29.70) | 47 (31.33) | – | 230 (31.42) | 241 (28.86) | – | 443 (44.48) |
| **EE** |     |     |     |     |     |     |     |     |          |             |
| N      | 99,917 | 77  | 512 | 19,650 | 7352 | 5652 | 1   | 1   | 7        | 67,262      |
| Age, years | 67.69 ± 14.38 | 65.16 ± 13.88 | 70.24 ± 15.32 | 66.79 ± 14.82 | 64.72 ± 14.56 | 66.87 ± 14.73 | 69  | 89  | 59.86 ± 23.97 | 68.33 ± 14.14 |
| < 65 years | 34,573 (34.60) | 33 (42.86) | 151 (29.49) | 7281 (37.05) | 3203 (43.57) | 2039 (36.08) | 0 (0) | 0 (0) | 5 (71.43) | 22,098 (32.85) |
| ≥ 65 years | 65,344 (65.40) | 44 (57.14) | 361 (70.51) | 12,369 (62.95) | 4149 (56.43) | 3613 (63.92) | 1 (100) | 1 (100) | 2 (28.57) | 45,164 (67.15) |
| Sex    |     |     |     |     |     |     |     |     |          |             |
| Male   | 56,465 (56.51) | 55 (71.43) | 253 (49.41) | 10,358 (52.71) | 3822 (51.99) | 3131 (55.4) | 1 (100) | 0 (0) | 2 (28.57) | 39,181 (58.25) |
| Female | 43,452 (43.49) | 22 (28.57) | 259 (50.59) | 9292 (47.29) | 3530 (48.01) | 2521 (44.6) | 1 (100) | 1 (100) | 5 (71.43) | 28,081 (41.75) |
| **ES** |     |     |     |     |     |     |     |     |          |             |
| N      | 26,039 | 76  | 427 | 9897 | 3510 | 2899 | 1   | 1   | 0        | 9800        |
| Age, years | 69.71 ± 13.47 | 68.26 ± 13.54 | 70.27 ± 14.45 | 70.99 ± 13.64 | 68.96 ± 13.52 | 70.34 ± 13.46 | 80  | –   | 71.50 ± 14.62 | 68.35 ± 13.21 |
| < 65 years | 8212 (31.54) | 21 (27.63) | 127 (29.74) | 2752 (27.81) | 1204 (34.30) | 867 (29.91) | 0 (0) | –   | 2 (50) | 3446 (35.16) |
| ≥ 65 years | 17,827 (68.46) | 55 (72.37) | 300 (70.26) | 7145 (72.19) | 2306 (65.70) | 2032 (70.09) | 1 (100) | –   | 2 (50) | 6354 (64.84) |
| Sex    |     |     |     |     |     |     |     |     |          |             |
| Male   | 16,053 (61.65) | 53 (69.74) | 266 (62.30) | 5706 (57.65) | 2159 (61.51) | 1716 (59.19) | 0 (0) | –   | 3 (75) | 6528 (66.61) |
| Female | 9986 (38.35) | 23 (30.26) | 161 (37.70) | 4191 (42.35) | 1351 (38.49) | 1183 (40.81) | 1 (100) | –   | 1 (25) | 3272 (33.39) |

Results are given as mean ± SD or number (%)
The table summarizes the data at the date of the first record of either CA, EE, or ES, whichever came earlier, between 2012 and 2015
CA catheter ablation, DEX dexmedetomidine, DZP diazepam, EE endoscopic examination, ES endoscopic surgery, FZP flunitrazepam, MDZ midazolam, PF propofol, SD standard deviation, TIA thiamylal, TIO thiopental
Fig. 1 Time trends for sedative utilization proportions from 2012 to 2015 by procedure. a Catheter ablation. b Endoscopic examination. c Endoscopic surgery. The year was defined as the interval from 1 April to the following 31 March. The proportion of each sedative includes both single and combination use of the sedative. The proportion was calculated using as the denominator the sum of each procedure. CA catheter ablation, DEX dexmedetomidine, DZP diazepam, EE endoscopic examination, ES endoscopic surgery, FZP flunitrazepam, MDZ midazolam, PF propofol, SD standard deviation, TIA thiamyal, TIO thiopental.
endoscopic procedures, the proportion was largest for EE of the upper bowel (86.9%) (Fig. 2b).

### 3.4 Time Trend for Sedative-Analgesic Combinations

Figure 3 displays the top five sedative-analgesic combinations, which accounted for >10% of all combinations in each year. Combination patterns were more diverse for CA than for endoscopy.

For CA, the top five combinations changed each year, resulting in nine combinations to appear in the end in 2015. The combinations of DEX + PF + TIA + PTZ and PF + TIA + PTZ were used the most during 2012 (15% for each), followed by DEX + TIA + PTZ (10%), DEX + PF + PTZ (8%), and DEX + PF + TIO + PTZ and DEX + PTZ (7%) (Fig. 3a). In 2015, DEX + PF + TIO + PTZ was used the most (15%), followed by PF + TIA + PTZ (11%), DEX + TIA + PTZ (9%), DEX + PF + PTZ (8%), and DEX (5%). From 2012 to 2015, use of DEX + PF + TIA + PTZ decreased from 15 to 1% and DEX + PF + TIO + PTZ increased from 7 to 15%. Among analgesics, PTZ alone ranked in the top five places.

For endoscopy, the same five combinations ranked among the top five places for use in EE and ES; however, the order of those five differed between the procedures. For EE, MDZ was used the most in 2012 (36%), followed by DZP (24%), FZP (17%), MDZ + PET (12%), and MDZ + PTZ (5%) (Fig. 3b). MDZ was also used the most in 2015 (44%), followed by DZP (19%), FZP (15%), MDZ + PET (11%), and MDZ + PTZ (6%). The order did not change throughout the study period, with MDZ remaining at the top, although the proportion of MDZ increased from 2012 to 2015. For ES, MDZ + PTZ was used the most in 2012 (23%), followed by MDZ (18%), MDZ + PET (13%), DZP (10%), and FZP (9%) (Fig. 3c). MDZ + PTZ was also used the most in 2015 (24%), followed by MDZ (18%), MDZ + PET (15%), DZP (9%), and FZP (8%). The order did not change throughout the study period. Single-sedative administration of DZP and FZP slightly decreased from 2012 to 2015 (DZP: from 10 to 9%, FZP: from 9 to 8%, respectively).

### 3.5 Time Trend of Complications

The occurrence of complications did not change throughout the period for any of the procedures (Table 2). In 2015, bradycardia was most commonly observed for CA (63.6%), followed by nausea and vomiting (24.9%), tachycardia (4.5%), and respiratory depression (0.3%). Nausea and vomiting was most commonly observed for EE (45.0%), followed by respiratory depression (8.5%), bradycardia (4.5%), and hypertension (0.8%). Respiratory depression was most commonly observed for ES (26.8%), followed by nausea and vomiting (16.8%), bradycardia (4.6%), hypertension (1.9%), and tachycardia (0.1%).

### 3.6 Complications by the Top Five Sedative-Analgesic Combinations

Because there were no changes in trends from 2012 to 2015, we calculated the occurrence of complications by the top five sedative-analgesic combinations only in 2015 (Table 3).

For CA, respiratory depression was not observed in patients receiving the top five sedative-analgesic combinations (Table 3). The occurrence of bradycardia for the utilization including DEX was 77.6% for DEX alone, 74.6% for DEX + TIA + PTZ, 68.7% for DEX + PF + TIO + PTZ, and 51.0% for DEX + PF + PTZ. Bradycardia in patients on utilization not including DEX (i.e., PF + TIA + PTZ) was 25.8%. In less than 10% of patients receiving the top five
combinations, tachycardia was observed. The occurrence of nausea and vomiting was 78.5% for DEX + TIA + PTZ, followed by 42.7% for DEX + PF + TIO + PTZ, 23.6% for PF + TIA + PTZ, 5.6% for DEX, and 4.5% for DEX + PF + PTZ.

For those undergoing EE, the occurrence of respiratory depression in combinations including MDZ was 51.6% for MDZ + PTZ, 35.6% for MDZ + PET, and 24.5% for MDZ (Table 3). For those taking the combinations not including MDZ, respiratory depression was observed in 5.3% for DZP and 4.5% for FZP. Bradycardia was observed by the
Table 2  Occurrences of complications by procedure from 2012 to 2015

|       | 2012      | 2013      | 2014      | 2015      |
|-------|-----------|-----------|-----------|-----------|
| CA    |           |           |           |           |
| N     | 1636      | 1972      | 2292      | 2646      |
| Bradycardia | 993 (60.7) | 1218 (61.8) | 1420 (62.0) | 1682 (63.6) |
| Nausea and vomiting | 389 (23.8) | 490 (24.8) | 558 (24.3) | 659 (24.9) |
| Tachycardia  | 70 (4.3)  | 110 (5.6) | 131 (5.7) | 118 (4.5) |
| Respiratory depression | 9 (0.6)  | 3 (0.2)   | 5 (0.2)   | 7 (0.3)   |
| EE     |           |           |           |           |
| N     | 158,826   | 165,660   | 164,095   | 160,211   |
| Nausea and vomiting | 63,298 (39.6) | 68,004 (41.1) | 70,342 (42.9) | 72,090 (45.0) |
| Respiratory depression | 11,853 (7.4) | 13,665 (8.2) | 14,322 (8.7) | 13,676 (8.5) |
| Bradycardia | 1454 (0.9) | 1182 (0.7) | 815 (0.5) | 769 (0.5) |
| Hypotension | 568 (0.4) | 667 (0.4) | 509 (0.3) | 525 (0.3) |
| Hypertension | 244 (0.2) | 226 (0.1) | 218 (0.1) | 168 (0.1) |
| Tachycardia  | 19 (0.0)  | 27 (0.0)  | 27 (0.0)  | 23 (0.0)  |
| ES     |           |           |           |           |
| N     | 39,708    | 42,548    | 42,317    | 42,624    |
| Respiratory depression | 9686 (24.8) | 11,255 (26.5) | 11,440 (27.0) | 11,422 (26.8) |
| Nausea and vomiting | 7843 (19.8) | 7645 (18.0) | 7336 (17.3) | 7159 (16.8) |
| Bradycardia | 2415 (6.1) | 2271 (5.3) | 2112 (5.0) | 1940 (4.6) |
| Hypotension | 826 (2.0) | 1021 (2.4) | 846 (2.0) | 789 (1.9) |
| Hypertension | 288 (0.7) | 273 (0.6) | 331 (0.8) | 347 (0.8) |
| Tachycardia  | 17 (0.0)  | 13 (0.0)  | 14 (0.0)  | 28 (0.1)  |

Results are given as number (%)

Complications included were respiratory depression, hypertension, hypotension, tachycardia, bradycardia, and nausea and vomiting.

For CA, hypertension and hypotension were excluded from the analysis because the prophylactic medications are usually administered for blood pressure fluctuation during the procedure.

We operationally defined the complications by the records of drug prescription, medical procedures, and medical devices (e.g., oxygen mask) that are commonly administered to counteract the corresponding symptoms (Supplementary Table 4 in the electronic supplementary material (ESM)).

We counted only the complications that occurred on the same date, but not on the day before, of CA, EE, or ES. Respiratory depression during EE and ES, however, were counted, regardless of the occurrence on the previous day of the procedure.

CA catheter ablation, EE endoscopic examination, ES endoscopic surgery.
Sedative Utilization Trends in Clinical Practice

12.1% of the patients receiving MDZ + PTZ but ≤ 1% of those who received other combinations. The occurrence of nausea and vomiting in patients on combinations of sedatives and analgesics was 25.4% for MDZ + PET and 24.5% for MDZ + PTZ. Those with sedatives alone were 55.7% for DZP, 44.6% for MDZ, and 39.1% for FZP. In less than 2% of the patients who received one of the top five combinations, hypertension, hypotension, or tachycardia were observed.

For those undergoing ES, the occurrence of respiratory depression in those with the combinations including MDZ was 54.4% for MDZ + PTZ, 48.6% for MDZ + PET, and 38.5% for MDZ (Table 3). Those with the combinations not including MDZ were 20.9% for FZP and 5.4% for DZP. The occurrence of nausea and vomiting with the combinations of sedatives and analgesics was 22.0% for MDZ + PTZ and 13.5% for MDZ + PET. Those with sedatives alone were 15.7% for FZP, 12.7% for MDZ, and 9.1% for DZP. In less than 10% of the patients who received any of the top five combinations, bradycardia, tachycardia, hypotension, or hypertension were observed.

Table 3  Occurrences of complications for the top five sedative-analgesic combinations by procedure

| Rank | Combination        | N  | Bradycardia | Nausea and vomiting | Tachycardia | Respiratory depression | Hypertension | Hypotension |
|------|-------------------|----|-------------|---------------------|------------|------------------------|--------------|------------|
|      |                   |    | n (%)       | n (%)               | n (%)      | n (%)                  | n (%)        | n (%)      |
| CA   |                   |    |             |                     |            |                        |              |            |
| 1    | DEX + PF + TIO + PTZ | 300 | 206 (68.7)  | 128 (42.7)          | 18 (6.0)   | 0 (0)                  | –            | –          |
| 2    | PF + TIA + PTZ    | 225 | 58 (25.8)   | 53 (23.6)           | 4 (1.8)    | 0 (0)                  | –            | –          |
| 3    | DEX + TIA + PTZ   | 181 | 135 (74.6)  | 142 (78.5)          | 1 (0.6)    | 0 (0)                  | –            | –          |
| 4    | DEX + PF + PTZ    | 157 | 80 (51.0)   | 7 (4.5)             | 2 (1.3)    | 0 (0)                  | –            | –          |
| 5    | DEX               | 107 | 83 (77.6)   | 6 (5.6)             | 9 (8.4)    | 0 (0)                  | –            | –          |
| EE   |                   |    |             |                     |            |                        |              |            |
| 1    | MDZ               | 22,982 | 78 (0.3)   | 10,241 (44.6)      | 3 (0.0)    | 5635 (24.5)           | 51 (0.2)    | 17 (0.1)   |
| 2    | DZP               | 10,072 | 53 (0.5)    | 5608 (55.7)        | 2 (0.0)    | 535 (5.3)             | 39 (0.4)    | 5 (0.0)    |
| 3    | FZP               | 7707  | 4 (0.1)     | 3016 (39.1)        | 0 (0)      | 343 (4.5)             | 9 (0.1)     | 2 (0.0)    |
| 4    | MDZ + PET         | 5797  | 56 (1.0)    | 1470 (25.4)        | 0 (0)      | 2061 (35.6)           | 11 (0.2)    | 3 (0.1)    |
| 5    | MDZ + PTZ         | 3016  | 364 (12.1)  | 739 (24.5)         | 0 (0)      | 1557 (51.6)           | 38 (1.3)    | 7 (0.2)    |
| ES   |                   |    |             |                     |            |                        |              |            |
| 1    | MDZ + PTZ         | 6454  | 500 (7.7)   | 1419 (22.0)        | 6 (0.1)    | 3514 (54.4)           | 295 (4.6)   | 39 (0.6)   |
| 2    | MDZ               | 4929  | 61 (1.2)    | 624 (12.7)         | 2 (0.0)    | 1900 (38.5)           | 59 (1.2)    | 25 (0.5)   |
| 3    | MDZ + PET         | 3980  | 382 (9.6)   | 537 (13.5)         | 0 (0)      | 1935 (48.6)           | 41 (1.0)    | 14 (0.4)   |
| 4    | DZP               | 2410  | 195 (8.1)   | 220 (9.1)          | 0 (0)      | 130 (5.4)             | 16 (0.7)    | 6 (0.2)    |
| 5    | FZP               | 2203  | 9 (0.4)     | 345 (15.7)         | 1 (0.0)    | 461 (20.9)            | 11 (0.5)    | 7 (0.3)    |

Because the trend of complications did not change from 2012 to 2015, we calculated the occurrence of complications for the top five combinations only in 2015

Complications included were respiratory depression, hypertension, hypotension, tachycardia, bradycardia, and nausea and vomiting

Hypertension and hypotension were excluded from the CA analysis because the medications are usually administered prophylactically for blood pressure fluctuation during the procedure

We operationally defined the complications by the records for drug prescription, medical procedures, and medical devices (e.g., oxygen mask) that are commonly administered to counteract the corresponding symptoms (Supplementary Table 4 in the electronic supplementary material)

We counted only the complications that occurred at the same date, but not on the day before, CA, EE, or ES. Respiratory depression during EE and ES, however, was counted regardless of the occurrence on the previous day of the procedure

CA catheter ablation, DEX dexmedetomidine, DZP diazepam, EE endoscopic examination, ES endoscopic surgery, FZP flunitrazepam, MDZ midazolam, PET pethidine, PF propofol, PTZ pentazocine, SD standard deviation, TIA thiamylal, TIO thiopental

4 Discussion

Using a large “real world” database, this study investigated changes in trends of sedation practice and complications after the approval of an additional indication (i.e., procedural sedation) for DEX in 2013. Since 2013, DEX has become more widely used for CA sedation. During endoscopy, contrarily, for which DEX had rarely been used before 2013, the additional indication of DEX did not increase its use even after 2013, although other off-label agents have been continuously used. The trend of complications was not affected for any of the procedures.

DEX and PF were selected for longer and painful procedures, i.e., CA, and for endoscopic procedures, ES rather
than EE, possibly because of their stable level of sedation. The unique profile of DEX, particularly its analgesic effect [7, 15], may have rendered it a desirable option for severely painful CA. DEX may also be beneficial for lengthy endoscopic procedures that induce pain (e.g., endoscopic submucosal dissection (ESD), endoscopic retrograde cholangiopancreatography (ERCP)) [20, 21]. Our further analysis of endoscopic procedures (ESD, ERCP, EMR, and others) indicated a tendency of DEX being used for longer procedures, such as ESD. Specifically, DEX was more frequently used for longer procedures (i.e., ESD: 83.7% (857/1024)) than comparatively shorter procedures (i.e., ERCP: 4.3% (44/1024) and endoscopic mucosal resection (EMR): 1.1% (11/1024)). PF was also mainly used for longer procedures (ESD: 63.7% (2847/4471); ERCP: 20.3% (906/4471); and EMR: 2.3% (101/4471)). For comparison, benzodiazepines (MDZ, DZP, and FZP) were more frequently used for shorter procedures (ERCP: 38.1% (30,004/78,648), 29.4% (8509/28,926), and 37.4% (8232/21,992), respectively; EMR: 18.9% (14,827/78,648), 25.0% (7244/28,926), and 22.1% (4865/21,992), respectively) than longer procedures (ESD: 14.7% (11,584/78,648), 11.5% (3327/28,926), and 12.2% (2693/21,992) among respective benzodiazepines). DEX may be less suitable for short-duration procedures, because DEX takes 15–25 min until reaching the target plasma concentration level [22], resulting in more use in longer procedures.

Benzodiazepines predominated for endoscopic procedures, consistent with previous reports from Japan [16]. Because endoscopic procedures, particularly EE, take only a short time, benzodiazepines, which can be administered as a single injection or infusion, may be preferred, particularly MDZ, which is short acting. The analgesics PTZ (the only analgesic used for CA) and PET were frequently used. PTZ were selected for not being classified as narcotics, unlike ketamine, which was rarely used; while PET, a narcotic, was used possibly because it does not require a narcotic prescription, suppresses the gag reflex [3], and produces a sedative effect.

Barbiturates were used more often for CA than for endoscopy possibly because of the familiarity with their use during defibrillation among cardiologists [23]. Contrarily, barbiturates use among gastroenterologists are perhaps unlikely in daily practice. TIA and TIO have similar profiles, but the order of the use for CA reversed in 2015, which is difficult to explain with the available data.

Without information on adverse events available in the database, we operationally defined the complications using records of treatments generally administered to counteract these symptoms. Thus, treatments administered only for preventative purposes may have partially been included as complications. Irrespective of this compromise, the pattern of complications did not deviate largely from the safety profile of the sedatives that were commonly used for each procedure. For example, DEX induces sedation by sympatholytic effects through stimulation of α2A-adrenoceptors in the locus ceruleus, resulting in a minimized risk for respiratory depression to a greater extent than other sedatives, including PF [21], MDZ [21, 24], and TIA [25]. By increasing parasympathetic activity, however, DEX induces bradycardia.

The frequent utilization of DEX for CA may partly explain the high bradycardia incidence and rare respiratory depression incidence during CA. In contrast, respiratory depression occurred more frequently during EE and ES than during CA possibly because of the predominant MDZ utilization, which increases the risk for respiratory depression [1]. Regardless of the sedative used, the inherent risk of fatal cardiopulmonary depression necessitates close monitoring during sedation [4]. For optimal sedation, understanding each sedative’s profile and selecting and/or combining the sedatives and analgesics is vital according to the characteristics of the procedures and patients’ conditions.

There are some limitations to this study. First, the results are subject to selection bias as the Medical Data Vision database was derived from the hospital-based claims data obtained only from acute-care hospitals. Therefore, the study population might not represent the general population prescribed with sedation. Second, the database may not cover all of the relevant information (e.g., doses/dosages, monitoring). Nonetheless, with the large sample obtained, this study may depict the overall trend of procedural sedation in Japan.

Third, the absence of relevant data may make it difficult to confirm the purpose of the sedative prescription (e.g., as sedative or analgesic), even though we minimized the possibility of using some of the sedatives as an anesthetic by excluding patients who underwent general anesthesia. Lastly, the definitions adopted may not precisely represent the actual utilization or complications. Especially, we operationally defined complications by the records of prescriptions of drugs and medical devices that are commonly administered to counter complications, which may underestimate or overestimate the occurrence of complications. Our definition, however, may allow us to evaluate the occurrence of complications that require medical treatment.

5 Conclusion

We investigated the trends of sedative utilization and complications in clinical practice using a large, “real-world” database. DEX has become more widely used for CA after the approval of the additional indication (procedural sedation). The sedation trend did not change in endoscopic procedures, as the dominant use of benzodiazepines persisted. The trend of complications did not change after 2013.
Acknowledgements We would like to thank Hiroyuki Tada, Medical Data Vision Co., Ltd. (Tokyo, Japan), for insightful suggestion on conditions of data extraction, Takayuki Sawada, Shinji Terao, and Aya Murakami, Clinical Study Support, Inc., for assistance in statistical analysis, and Tatsuya Isomura and Emiko Sato, Clinical Study Support, Inc., for assistance in manuscript drafting.

Author contribution AM conceived the study. AM, MM, HS, YF, and YI designed the study. AM and MM acquired the data. MM and TL analyzed the data. AM, MM, TL, and YI interpreted the data. AM drafted the manuscript. All authors critically revised the manuscript and approved its final submitted version.

Compliance with Ethical Standards

This retrospective study used a preexisting de-identified claims database. The Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects do not apply to a study exclusively using the de-identified data. Therefore, this study was not obligated to apply for the ethical approval by institutional review board and informed consent.

Funding Financial support was provided by Pfizer Japan, Inc.

Conflicts of interest AM, MM, HS, and YF are employees of Pfizer Japan, Inc. TL is an employee of Clinical Study Support, Inc. YI declares no conflict of interest.

Data availability Data are purchased from Medical Data Vision, Co., Ltd (MDV, Tokyo, Japan). For inquiries on the dataset analyzed in this study, please contact MDV (https://www.mdv.co.jp/).

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology. 2007;133:675–701.
2. Okumura K, Aizawa Y, Aihara N, et al. Guidelines for indications and procedural techniques of catheter ablation. Circ J. 2012;3–67 (in Japanese). http://www.j-circ.or.jp/guideline/pdf/JCS2012_okumura_h.pdf. Accessed 13 Dec 2017.
3. Obara K, Haruma K, Irisawa A, et al. Naishikyou shinryou ni okeru okumura_h.pdf. Accessed 13 Dec 2017.
4. Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology. 2018;128(3):437–479
5. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003;98(2):428–36.
6. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–60.
7. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93(5):1345–9.
8. Bloor BC. General pharmacology of α2-adrenoceptors. Anesth Pharmacol. 1993;1:221–32.
9. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4(5):302–8.
10. Hsu YW, Cortinez LI, Robertson KM, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101(5):1066–76.
11. Ebert TJ, Hall JE, Barney JA, Ulrich TD, Colino MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382–94.
12. Nishida T, Nishimura M, Kagawa K, Hayashi Y, Mashimo T. The effects of dexmedetomidine on the ventilatory response to hypercapnia in rabbits. Intensive Care Med. 2002;28(7):969–75.
13. Candiotii KA, Bergese SD, Bokesch PM, et al. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010;110(1):47–56.
14. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992;77(6):1134–42.
15. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexametomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001;14(1):13–21.
16. Oda T, Takahama Y. Anesthetic consideration in patients undergoing catheter ablation for atrial fibillation. Masui (The Japanese Journal of Anesthesiology). 2012;61:1199–1204 (in Japanese).
17. Yoshino J, Igarashi Y, Ohara H, et al. Shoukakinaishikyouokuma_h.pdf. Accessed 13 Dec 2017.
18. Y. Procedural sedation with dexmedetomidine during ablation catheter ablation for atrial fibrillation. Masui (The Japanese Journal of Anesthesiology). 2012;61:1199–1204 (in Japanese).
19. Y. Shoukakinaishikyouokuma_h.pdf. Accessed 13 Dec 2017.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–8.
21. Takimoto K, Ueda T, Shimamoto F, et al. Sedation with dexmedetomidine hydrochloride during endoscopic submucosal dissection of gastric cancer. Digest Endosc. 2011;23(2):176–81.
22. Dexametomidine Pharmaceutical. interview form (available in Japanese). Tokyo: Pfizer Japan Inc; 2016.
23. Ogawa S, Aizawa Y, Atarashi H, et al. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2006–2007 Joint Working Groups Report). Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008). Circ J. 2008;72(Suppl 1V):1581–1638 (in Japanese). http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawas_h.pdf.
24. Cho JS, Shim JK, Na S, Park I, Kwak YL. Improved sedation with dexmedetomidine-remifentanil compared with midazolam-remifentanil during catheter ablation of atrial fibrillation: a randomized, controlled trial. Europace. 2014;16(7):1000–6.
25. Sairaku A, Yoshida Y, Hirayama H, Nakano Y, Ando M, Kihara Y. Procedural sedation with dexmedetomidine during ablation of atrial fibrillation: a randomized controlled trial. Europace. 2014;16(7):994–9.

△ Adis